NY-AQARA
23.11.2021 09:02:36 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, announced today the launch of its next-gen flagship home security camera, the Camera Hub G3. The new camera is a 2K, pan-and-tilt camera with the local facial and gesture recognition features, and it integrates a built-in Zigbee 3.0 hub, allowing the device to connect up to 128 Aqara accessories*. It is now available on the Aqara Amazon brand stores in the US , Canada and France , and is also expected to be sold by authorized Aqara retailers in North America, Europe and Asia in the following weeks**.
Thanks to a powerful NPU-equipped processor, the Aqara Camera Hub G3 supports facial recognition and gesture recognition features, both of which can be used to trigger home automations. Users can configure to receive push notifications when their young kids arrive home or when a stranger is detected (i.e. a familiar face was not detected), or to stop video recording when the face of a family member or a preset hand gesture is recognized. The AI-enabled features will make homes safer, and make people’s lives even easier as users can now trigger home automation with certain hand gestures or simply a recognized face.
The G3 camera hub also supports automatic cruising, face tracking as well as pet tracking, all enabled by the 110° wide-angle lens and the pan-and-tilt motor which provides up to 340° rotation angle. The pan-and-tilt motor can be controlled manually, by the preset cruising path, or via home automations (for example, to turn to the front door when Door & Window Sensor is triggered). Combined with the high-resolution 2304×1296 pixel sensor and the infrared night vision enabled by the 940 nm LEDs, which are invisible at night, the G3 protects homes in 360-degree with no blind spot, day and night.
Compared to the previous G2H Camera Hub, the new G3 provides other advanced features including:
- Wider compatibility with third-party platforms : as a camera it supports not only HomeKit Secure Video*** but also streaming to Amazon Alexa and Google Assistant smart displays, while as a hub it allows connected child devices to support a wide range of third-party ecosystems and voice assistants, such as HomeKit, Alexa, Google Home, IFTTT, and more;
- Local infrared control : the built-in IR controller allows the G3 to automate the infrared-compatible devices, and the IR automation is local which means it remains functioning without the Internet connection;
- Dual-band Wi-Fi support : both 2.4GHz and 5GHz Wi-Fi networks are supported;
- Privacy protection : it is equipped with a privacy shutter that physically covers the camera lens, and the shutter can be activated manually and automatically;
- Type-C port with video out : it uses the modern and universal connector that supports low-latency, high-definition video output via UVC protocol.
To celebrate the launch, Aqara is now offering limited-time discounts for the new Camera Hub G3 on its Amazon brand stores. North American customers will enjoy a 20% discount at check with the promo code USG3PRGE in the US and Canada , and the code will be valid through Nov 24, 2021. Aqara also offers French customers a 20€ OFF discount at its Amazon.fr store , with the promo code CAMERAG3FR, and the offering will expire on Nov 25, 2021.
For more details of the G3 camera hub, please visit our website .
* To connect up to 128 devices, Zigbee routers/repeaters such as Smart Wall Switch (With Neutral) and Smart Plug are required.
** Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
*** In HomeKit Secure Video mode, the camera records in Full HD 1080p and Pan/Tilt controls are not available due to the current limitations of HomeKit technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005627/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
